| Safety and efficacy of alcohol septal ablation in patients with symptomatic concentric left ventricular hypertrophy and outflow tract obstruction. | |
| | |
MedLine Citation:
|
PMID: 21127363 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
BACKGROUND: Transcoronary septal ablation is efficacious for patients with symptomatic hypertrophic obstructive cardiomyopathy (HOCM) and outflow-tract gradient (OTG). However, while patients with symptomatic concentric left ventricular hypertrophy (CLVH) may develop OTG, the safety and efficacy of septal ablation in these patients is unknown. OBJECTIVES: To determine the potential safety and efficacy of transcoronary alcohol septal ablation in refractory, symptomatic patients with CLVH and significant OTG. METHODS: We identified 9 patients (all female; age, 67.6 ± 8.7 years) with CLVH and OTG who underwent septal ablation on a compassionate basis and for symptomatic relief, with CLVH defined as left ventricular wall thickness > 15 mm in the absence of asymmetric septal hypertrophy. CLVH patients were compared with age-, sex- and OTGmatched HOCM patients (resting OTG, 56.7 ± 22.4 versus 58.3 ± 33.5 mmHg, respectively; p = 0.91). RESULTS: In CLVH patients, mean resting OTG decreased to 22.8 ± 12.5 mmHg (p < 0.0005 versus baseline), which was comparable to the change in HOCM patients (p = 0.45 CLVH versus HOCM). Peak inducible OTG in CLVH patients also decreased following septal ablation (142.2 ± 36.3 to 36.1 ± 16.2 mmHg; p < 0.0001). Baseline left ventricular end-diastolic pressure (LVEDP) was similar between CLVH (17.7 ± 3.7 mmHg) versus HOCM (16.3 ± 4.0 mmHg; p = 0.50). Following ablation, LVEDP decreased by 3.4 ± 1.9 mmHg in CLVH (p < 0.001 versus baseline) and 3.0 ± 2.2 mmHg in HOCM patients (p = 0.67 CLVH versus HOCM). Complication rates were similar between groups. Baseline New York Heart Association class was 3.6 ± 0.5 for CLVH versus 3.3 ± 0.5 for HOCM (p = 0.51). Both groups experienced symptomatic improvement following ablation (p < 0.0005), and at long-term follow up (34.9 ± 23.9 months), these changes were similar and sustained. CONCLUSION: Septal ablation holds promise for the management of symptomatic CLVH with OTG. |
| | |
Authors:
|
Jason C Kovacic; Deepak Khanna; Dheeraj Kaplish; Rucha Karajgikar; Samin K Sharma; Annapoorna Kini |
Related Documents
:
|
19690023 - Influence of trigger psa and psa kinetics on 11c-choline pet/ct detection rate in patie... 21543733 - Disease activity return during natalizumab treatment interruption in patients with mult... 16162903 - Non-hodgkin's lymphoma in systemic lupus erythematosus. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The Journal of invasive cardiology Volume: 22 ISSN: 1557-2501 ISO Abbreviation: J Invasive Cardiol Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-12-03 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8917477 Medline TA: J Invasive Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 586-91 Citation Subset: IM |
Affiliation:
|
Cardiac Catheterization Laboratory, Cardiovascular Institute, Mount Sinai Hospital, One Gustave L. Levy Place, New York, NY 10029, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Highly controlled vascular syringes for pericardiocentesis.
Next Document: Clinical and angiographic outcomes in elderly patients treated with endothelial progenitor cell capt...